FDA Approves Dupixent® (dupilumab) as First Treatment for Adults and Children Aged 12 and Older with Eosinophilic Esophagitis ...Middle East

TARRYTOWN, N.Y. and PARIS, May 20, 2022 /PRNewswire/ -- Dupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States; approval granted more than two months ahead of FDA's Priority Review action date Dupixent 300 mg weekly significantly improved...

Hence then, the article about fda approves dupixent dupilumab as first treatment for adults and children aged 12 and older with eosinophilic esophagitis was published today ( Friday 20/05/2022 - 10:30 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( FDA Approves Dupixent® (dupilumab) as First Treatment for Adults and Children Aged 12 and Older with Eosinophilic Esophagitis )

Also on site :

• Retired Gen. Wesley Clark tangled up in a crypto fraud suit with Burning Man buddies
• My Friend Invited Us for Dinner. When She Greeted Us at the Door, She Asked for Something Shocking.
• Iconic '80s Boy Band Impresses With 'Amazing' Live Performance